Slide 1: ASX Announcement
ASX Announcement 18 August 2026 FY26 Results Investor Briefing Cogstate Ltd (ASX:CGS) has today released an Investor Briefing that provides a summary of the financial results for the year ended 30 June 2026 and also provides commentary in respect of the business and financial outlook. The presentati
Slide 2: About Cogstate
About Cogstate Cogstate Ltd (ASX: CGS) is a neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive
Slide 3: FY26 Full Year Results
FY26 Full Year Results 18 August 2026 Brad O’Connor, CEO | Darren Watson, CFO | Rachel Colite, EVP Clinical Trials © 2026 Cogstate Ltd. All rights reserved.
Slide 4: Disclaimer
Disclaimer This presentation has been prepared by Cogstate Limited (‘Cogstate’). The information in this presentation is of a general nature and does not purport to be complete, nor does it contain all the information which would be required in a prospectus prepared in accordance with the requiremen
Slide 5: A landmark year achieved through diversification and expansion of offering
A landmark year achieved through diversification and expansion of offering. Delivered record sales, revenue and profit, while investing with discipline to support the next phase of growth. 3
Slide 6: Investment Highlights
Investment Highlights All figures in US$ unless otherwise stated 1 2 3 4 5 Record profitable Well-capitalised Sales inflection in a Unique competitive Technology-driven growth & visibility balance sheet growing market position margin expansion $60.9m revenue; 25% $34.8m net cash, no Strategic channe
Slide 7: FY26 Scorecard – A Record Breaking Year
FY26 Scorecard – A Record Breaking Year All figures in US$ and comparison is to previous corresponding period Trial Starts Contracted Revenue Sales Contracts Growth $89.0m up 116% 90 initiated (vs 35) Over time: $118.5m 171 running (vs 110) FY27: $48.3m, up 54% Gross Profit $35.4m Revenue $60.9m PBT
Slide 8: Profitable Growth at Scale
Profitable Growth at Scale Revenue & Profitability, by Financial Year 65 • Delivered sustained growth with 60 increasing profitability over time. 55 • FY26 demonstrates the operating 50 45 leverage in the model. 40 • 27% revenue growth 2H26 vs 1H26 US$ Millions 35 58% • 2H26 revenue growth delivered
Slide 9: Record Contracted Revenue Provides Forward Visibility
Record Contracted Revenue Provides Forward Visibility $118.5m, of which $48.3m expected to be recognised in FY27 50.0 • FY27 starts from a record base of committed revenue. 45.0 • Future growth still depends on in-period conversion of new contracts, but the starting position is materially stronger.
Slide 10: Trial Starts are Increasing, Portfolio is Diversifying
Trial Starts are Increasing, Portfolio is Diversifying Number of New Trial Starts, per Half FY26: 90 new trial starts (vs 35 FY25) 55 • 14% Alzheimer’s. 50 • 46% Mood, Sleep & Other Neurology. 45 • 33% Rare Diseases. 40 • 7% Cancer, Metabolic and Other Diseases. Number of Trials 35 30 25 • Record nu
Slide 11: Ongoing Trials by Phase and by Indication
Ongoing Trials by Phase and by Indication • Record number of ongoing trials: 171, up 55%. • Significant growth in mood, sleep & other neuro supports the expansion strategy. • Central rating is a key feature of mood trials, enhancing the average value of those trials for Cogstate. • 78 ongoing phase
Slide 12: Revenue Performance of Clinical Trials is Accelerating
Revenue Performance of Clinical Trials is Accelerating 35 33 2H26 Clinical Trials Revenue $32.7m 31 • 17% growth pcp and 27% growth compared to most recent half-year 29 - Strong second half consistent with recent years. 27 US$ Millions 25 • License fee revenue 24% of 2H26 revenue - 23% in 1H26 23 -
Slide 13: What’s driving increased sales opportunities?
What’s driving increased sales opportunities? Multiple drivers expanding Cogstate’s growth Indication expansion Expansion of offering Market conditions • Expanding beyond neurology (brain • Shift toward decentralised and remote • Growing CNS clinical trial activity is health) and aggressively into t
Slide 14: Partnerships Support Repeatable Growth
Partnerships Support Repeatable Growth • Strategic partnerships are embedding Cogstate solutions within leading clinical trial platforms. • These relationships broaden access to programs and support a more repeatable pipeline of opportunities. • Partnerships and integrations are an increasing contri
Slide 15: Financial Summary - Operational Leverage Evident
Financial Summary - Operational Leverage Evident FY26 FY25 Movement Key Points: Total Revenue $60.9m $53.1m 15% Revenue growth: • Expansion into new indications. Gross Profit $35.4m $32.4m 9% • Market expansion through partner model. Gross Margin 58% 61% (3% pts) • Offering strength with growth in c
Slide 16: Building an AI-enabled operating platform for modern CNS trials
Building an AI-enabled operating platform for modern CNS trials AI product enhancement, platform evolution • AI-enabled Rater Training and AI-enabled Central Monitoring are the first initiatives of a broader AI-enabled platform for regulated CNS trial workflows. • The next phase extends AI and autom
Slide 17: Capital Management Plans
Capital Management Plans Share Buyback As Cogstate’s revenue and profits grows, we expect the share price to continue to hit all-time highs. In this context, the share buyback will remain open, but we will be selective in utilising the buyback and seek to exploit market mispricing and times of volat
Slide 18: FY27 Outlook and Investment Plan
FY27 Outlook and Investment Plan Record Contracted Future Revenue • $48.3 million expected to be recognised in FY27 (up 54%). • Market conditions remain positive. • Revenue growth expected, subject to level and timing of sales contracts executed throughout FY27. Technology Investment • Investing pur
Slide 19: Record FY26 performance is not the destination
Record FY26 performance is not the destination It’s the foundation for the next phase of growth, supported by increasing CNS trial activity, expanding market reach, stronger revenue visibility and technology- enabled scalability. • Stronger starting position - FY27 begins with a record contracted re
Slide 20: Cogstate
GI Cogstate